Scientific Programme Monday, 09 September 2019 09:00
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
University Medical Center of the University of Groningen Research Portfolio
University Medical Center of the University of Groningen Research portfolio Research Institutes and Research Programmes UMCG’s multidisciplinary Research Programmes are organised in five Research Institutes. Each Institute covers a specific part of the UMCG research area. By establishing numerous international research projects and strategic alliances over the past, research within the Institutes bridged national boundaries. Especially for the UMCG focus "Active and Healty Ageing" international collaboration is required and prepares the UMCG to contribute to this global challenge. For every UMCG Research Programme the relevance for Healthy Ageing is defined. Regarding the training and education of future scientists (MSc and PhD) the five Research Institutes collaborate in the Graduate School of Medical Sciences assuring the incorporation of state of the art scientific know-how. 1. GUIDE Institute: Chronic Diseases and Drug Exploration 2. BCN-BRAIN Institute: Behavioural and Cognitive Neurosciences 3. SHARE Institute: Health Research and Epidemiology 4. W.J.Kolff Institute: Biomaterials 5. CRCG Institute: Fundamental, Clinical and Translational Cancer Research Some of the Research Programmes are Platform Programmes, embedded in and supporting all five Research Institutes. Contents: Research programmes GUIDE 02-26 Research programmes BCN-BRAIN 27-35 Research programmes SHARE 36-46 Research programmes CRCG 47-55 Research programmes W.J. Kolff 56-65 Platform programme Center Medical Imaging 66-68 1 RESEARCH INSTITUTE GUIDE: Chronic Diseases and Drug Exploration 1. Biopharmaceuticals, Discovery, Design and Delivery (GUIDE-BDDD) Programme leaders: prof. dr. H.W. Frijlink, prof. dr. K. Poelstra Mission The BDDD Division explores innovative approaches oriented towards the early phase of drug development up to the use of these approaches in practice. -
Who Wants to Live Forever? Reader’S Digest
HEALTH Who Wantsto Live Forever? As a species, we humans appear to be the undisputed masters of our planet. Moreover, since Yuri Gagarin’s inaugural space flight in 1961, we can even leave the confines of Earth to travel in space. Yet, we have one Achilles’ heel—we’re mortal BY CHRIS MENON 1234567890 1234567890 36 BRAIN LIGHT/ALAMY STOCK PHOTO WHO WANTS TO LIVE FOREVER? READEr’s DIGEST T 122 YEARS, THE MAXIMUM HUMAN LIFESPAN lags well behind some species of giant tortoise (188 years), Greenland shark (400 years) and the record set by the lowly Icelandic clam (507 years). Even those relatively few humans who do manage to make it past 100—some 14,570 people in the UK in 2015—are invariably bedeviled byA poor health. Recently, efforts to extend the healthy of Amazon, has similarly invested human lifespan have achieved much in Unity Biotechnology, which aims publicity following the backing of “to design therapeutics that prevent, visionary, super-rich Silicon Valley halt, or reverse diseases of ageing”. tech entrepreneurs. In 2013, Google’s Unity intends to develop a new founders created a subsidiary class of therapies called “senolytic company called Calico (short for medicines”, designed to selectively the California Life Company), eliminate senescent cells. Senescent Billionaire researchers, which promptly hired a team of top cells accumulate with age and, Some believe that death, Arthur Levinson, Jeff technologies that scientists and now has more than unlike normal cells, they secrete like any disease, can be Bezos and Elon Musk the SENS Research £1bn in the bank to fund its work. -
Tuesday 24Th
Matchmaking event University of Groningen/UMCG and University of Chile 24-25 September, 2019 Time slot Tuesday 24th Location 09:00-10:30 Health Kick-off ERIBA Seminar Room 10:30-11:00 Break ERIBA Pantry 11:00-13:00 Parallel session Time Neuroscience & Biology of ageing (ERIBA seminar room) Time Oncology & Drug Delivery (Room 16) 11:00-11:25 Felipe Court: 11:00-11:20 Andrew Quest: Necroaxoptosis: a novel axonal degenerative mechanism involved in pathologies of the ageing nervous system From tumor suppressor to metastasis promoter – Caveolin-1, a Jack-of-all trades in cancer 11:25-11:40 Marco Demaria: 11:20-11:40 Frank Kruyt: Role of cellular senescence in health and disease Brain tumors: glioblastoma stem cell models and identification of new therapeutic targets 11:40-12:02 Miguel Concha: 11:40-12:00 Marcelo Kogan: Nothobranchious furzeru as a model of aging and neurodegeneration Nanoplatforms for drug delivery, theraphy and diagnostic of chronic diseases 12:05-12:20 Harrie Kampinga: 12:00-12:20 Paul de Vos: Protein homeostasis and age-related protein aggregation diseases Carbohydrates and microbiota in health 12:20-12:45 Christian González-Billault: 12:20-12:40 Inge Zuhorn: Understanding neuronal aging using cell culture models Drug Delivery across the Blood-Brain Barrier 12:45-13:00 Amalia Dolga: 12:40-13:00 Wijnand Helfrich: Targeting mitochondria in human neurodegenerative disease model systems Novel Targeted approaches in Cancer Immunotherapy 13-14:30 Lunch ERIBA Pantry 15:00-17:30 Parallel session Time Neuroscience & Biology of ageing -
From Here to Immortality: Anti-Aging Medicine
FromFrom HereHere toto Immortality:Immortaalitty: AAnti-AgingAnnntti-AAgging MMedicineedicine Anti-aging medicine is a $5 billion industry. Despite its critics, researchers are discovering that inter ventions designed to turn back time may prove to be more science than fiction. By Trudie Mitschang 14 BioSupply Trends Quarterly • October 2013 he symptoms are disturbing. Weight gain, muscle Shifting Attitudes Fuel a Booming Industry aches, fatigue and joint stiffness. Some experience The notion that aging requires treatment is based on a belief Thear ing loss and diminished eyesight. In time, both that becoming old is both undesirable and unattractive. In the memory and libido will lapse, while sagging skin and inconti - last several decades, aging has become synonymous with nence may also become problematic. It is a malady that begins dete rioration, while youth is increasingly revered and in one’s late 40 s, and currently 100 percent of baby boomers admired. Anti-aging medicine is a relatively new but thriving suffer from it. No one is immune and left untreated ; it always field driven by a baby- boomer generation fighting to preserve leads to death. A frightening new disease, virus or plague? No , its “forever young” façade. According to the market research it’s simply a fact of life , and it’s called aging. firm Global Industry Analysts, the boomer-fueled consumer The mythical fountain of youth has long been the subject of base will push the U.S. market for anti-aging products from folklore, and although it is both natural and inevitable, human about $80 billion now to more than $114 billion by 2015. -
SENS-Research-Foundation-2019
by the year 2050, cardiovascular an estimated 25-30 the american 85 percent of adults disease years and older age 85 or older remains the most population will suffer from common cause of 2 1 2 dementia. death in older adults. triple. THE CLOCK IS TICKING. By 2030, annual direct The estimated cost of medical costs associated dementia worldwide was 62% of Americans with cardiovascular $818 billion diseases in the united over age 65 have in 2015 and is states are expected to more than one expected to grow to rise to more than chronic condition.1 3 $2 trillion $818 billion. by 2030.1 References: (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732407/, (2) https://www.who.int/ageing/publications/global_health.pdf, (3) https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity sens research foundation board of directors Barbara Logan Kevin Perrott Bill Liao Chairperson Treasurer Secretary Michael Boocher Kevin Dewalt James O’Neill Jonathan Cain Michael Kope Frank Schuler 02 CONTENTS 2019 Annual Report 04 Letter From The CEO 06 Outreach & Fundraising 08 Finances 09 Donors erin ashford photography 14 Education 26 Investments 20 Conferences & Events 30 Research Advisory Board 23 Speaking Engagements 31 10 Years Of Research 24 Alliance 32 MitoSENS 34 LysoSENS 35 Extramural Research 38 Publications 39 Ways to Donate cover Photo (c) Mikhail Leonov - stock.adobe.com special 10th anniversary edition 03 FROM THE CEO It’s early 2009, and it’s very late at night. Aubrey, Jeff, Sarah, Kevin, and Mike are sitting around a large table covered in papers and half-empty food containers. -
Annual Report V2.Indd 1 16-07-2020 20:59 Welcome to Our Annual Report 2019
European Research Institute for the Biology of Ageing Annual Report 2019 ERIBA | Cover .indd Alle pagina's 30-06-2020 13:49 Annual Report 2019 2019 ERIBA | Annual Report V2.indd 1 16-07-2020 20:59 Welcome to our Annual Report 2019 Coordination: Gerald de Haan and Megha Upadhyay Secretarial Support: Sylvia Hoks, Annet Vos-Hassing & Alida de Haan ژيƺɀǣǕȇƏȇƳXǼǼɖɀɎȸƏɎǣȒȇɀ) Stefan Heinrich ژيȸǣȇɎǣȇǕ¨ Ridderprint BV | Anand Baldew Copies: 100 ERIBA | Annual Report V2.indd 2 16-07-2020 20:59 Annual Report Table of contents 1. Foreword by the Director 4 2. Ageing Research at ERIBA 6 3. 2019: Highlights 10 4.Facts and Figures 20 אא ³ƬǣƺȇɎǣˡƬ¨ɖƫǼǣƬƏɎǣȒȇɀٮ -Funding/Grants 32 -Invited Speakers 35 אג ƺȒȵǼƺ¨ٮ 5.Facilities 46 6.Education 50 7.Outreach & Dissemination 54 זד ³ƬǣƺȇɎǣˡƬƳɮǣɀȒȸɵ ȒƏȸƳِז 9.Sponsors 59 ERIBA | Annual Report V2.indd 3 16-07-2020 20:59 Foreword by the Director 2019 in review It is a great pleasure to present to you the 2019 Annual Report of the European Research Institute for the Biology of Ageing. This report provides you with an overview of all our activities and achievements, in science, education, business development and outreach. We value all these domains equally, and are proud to share with you all that has been accomplished in 2019. I write these words in the midst of the Covid-19 pandemic. This pandemic may very well have a major effect on global research and education for quite some time to come. One aspect, highly relevant to what we do in ERIBA, relates to how the virus differentially affects individuals in society. -
Shared Ageing Research Models (Sharm): a New Facility to Support Ageing Research
Biogerontology (2013) 14:789–794 DOI 10.1007/s10522-013-9457-0 METHOD Shared Ageing Research Models (ShARM): a new facility to support ageing research Adele L. Duran • Paul Potter • Sara Wells • Tom Kirkwood • Thomas von Zglinicki • Anne McArdle • Cheryl Scudamore • Qing-Jun Meng • Gerald de Haan • Anne Corcoran • Ilaria Bellantuono Received: 5 July 2013 / Accepted: 16 August 2013 / Published online: 2 October 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com Abstract In order to manage the rise in life expec- Wellcome Trust, open to all investigators. It collects, tancy and the concomitant increased occurrence of stores and distributes flash frozen tissues from aged age-related diseases, research into ageing has become murine models through its biorepository and provides a strategic priority. Mouse models are commonly a database of live ageing mouse colonies available in utilised as they share high homology with humans and the UK and abroad. It also has an online environment show many similar signs and diseases of ageing. (MICEspace) for collation and analysis of data from However, the time and cost needed to rear aged communal models and discussion boards on subjects cohorts can limit research opportunities. Sharing of such as the welfare of ageing animals and common resources can provide an ethically and economically endpoints for intervention studies. Since launching in superior framework to overcome some of these issues July 2012, thanks to the generosity of researchers in but requires dedicated infrastructure. Shared Ageing UK and Europe, ShARM has collected more than Research Models (ShARM) (www.ShARMUK.org) 2,500 tissues and has in excess of 2,000 mice regis- is a new, not-for-profit organisation funded by tered in live ageing colonies. -
5 EVENTS in ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland
FIFTH ANNUAL - LIFE SCIENCE R&D DATA INTELLIGENCE LEADERS FORUM Basel, Switzerland January 23-24th, 2018 Optional Workshop 22nd, January Hear keynote presentations from the experts: Etzard Stolte Global Head Knowledge Management Roche, Switzerland Abhimanyu Verma 5 EVENTS IN ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland Day 1: Torsten Niederdraenk Head of Technology Center Strategic Developments in R&D Big Siemens Healthcare, Germany Data Catherine Brownstein Scientific Director Day 2 (am): Stream 1 Manton Center for Orphan Disease Research Boston Children’s Hospital, USA Discovery & Omics Data Excellence Navin Ramachandran Radiology Consultant Day 2 (am): Stream 2 University College London Hospitals NHS Foundation Trust, Healthcare specialist in distributed ledgers and IoT Clinical & Patient Level Data IOTA Foundation, UK Excellence Marie-Claire Peakman Executive Director, Head Hit Discovery & Lead Profiling, Medicine Design Day 2 (pm): Stream A Pfizer, USA R&D IT & Bioinformatics Alex Zhavoronkov Co-founder, Insilico Medicine, CSO Day 2 (pm): Stream B The Biogerontology Research Foundation, UK Ivana Schnur Digital Health Collaborations Co-founder, CMO Sense.ly, USA Pre-Event Workshop: Jan 22nd Paul Wicks Artificial Intelligence for Drug Vice President of Innovation PatientsLikeMe, UK Discovery: Workshop for Senior Jazz Panchoo Global Strategy Head, VP, Digital Platforms Executives Ascensia Diabetes Care, Switzerland This Event is Certified for Continuing Professional Development with more than 30 presentations -
Viewer Comments
Article Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis Graphical abstract Authors Christopher D. Wiley, Rishi Sharma, Sonnet S. Davis, ..., Marco Demaria, Arvind Ramanathan, Judith Campisi Correspondence [email protected] (C.D.W.), [email protected] (A.R.), [email protected] (J.C.) In brief Senolytics, transgenic, and pharmacological interventions that selectively kill senescent cells are currently in clinical trials aiming to treat age-related degenerative pathologies. Here, Wiley et al. discover that senescent cells produce multiple signaling lipids known as oxylipins. One oxylipin, dihomo-15d-PGJ2, promotes features of senescence by activating RAS and is released from cells during senolysis, serving as the first biomarker of the Highlights process in culture and in vivo. d Senescent cells make several oxylipins, dihomo- prostaglandins, and leukotrienes d Dihomo-15d-PGJ2 is intracellular during senescence and released during senolysis d Dihomo-15d-PGJ2 activates RAS, promoting senescence and the SASP d Positive feedback between prostaglandins, RAS, and p53 maintains senescence Wiley et al., 2021, Cell Metabolism 33, 1–13 June 1, 2021 ª 2021 Published by Elsevier Inc. https://doi.org/10.1016/j.cmet.2021.03.008 ll Please cite this article in press as: Wiley et al., Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis, Cell Metabolism (2021), https://doi.org/10.1016/j.cmet.2021.03.008 ll Article Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis Christopher D. Wiley,1,2,* Rishi Sharma,1 Sonnet S. Davis,1 Jose Alberto Lopez-Dominguez,1 Kylie P. Mitchell,1 Samantha Wiley,1 Fatouma Alimirah,1 Dong Eun Kim,1 Therese Payne,1 Andrew Rosko,1 Eliezer Aimontche,1 Sharvari M. -
Read Our New Annual Report
The seeds of a concept. The roots of an idea. The potential of a world free of age-related disease. Photo: Sherry Loeser Photography SENS Research Foundation Board of Directors Barbara Logan, Chair Bill Liao, Secretary Kevin Perrott, Treasurer Michael Boocher Jonathan Cain Kevin Dewalt Michael Kope Jim O’Neill Frank Schüler Sherry Loeser Photography 2 Contents CEO Letter (Jim O’Neill) 4 Finances 5 Donors 6 - 7 Fundraising & Conferences 8 - 9 Around the World with Aubrey de Grey 10 Outreach 11 Founding CEO Tribute & Underdog Pharmaceuticals 12 - 13 Investments 14 Welcome New Team Members 15 Education 16 - 17 Publications & Research Advisory Board 18 Research Summaries 19 - 22 Ways to Donate 23 The SRF Team Front row: Anne Corwin (Engineer/Editor), Amutha Boominathan (MitoSENS Group Lead), Alexandra Stolzing (VP of Research), Aubrey de Grey (Chief Science Officer), Jim O’Neill (CEO), Bhavna Dixit (Research Associate). Center row: Caitlin Lewis (Research Associate), Lisa Fabiny-Kiser (VP of Operations), Gary Abramson (Graphics), Maria Entraigues-Abramson (Global Outreach Coordinator), Jessica Lubke (Administrative Assistant). Back row: Tesfahun Dessale Admasu (Research Fellow), Amit Sharma (ImmunoSENS Group Lead), Michael Rae (Science Writer), Kelly Protzman (Executive Assistant). Not Pictured: Greg Chin (Director, SRF Education), Ben Zealley (Website/Research Assistant/ Deputy Editor) Photo: Sherry Loeser Photography, 2019 3 From the CEO At our 2013 conference at Queens College, Cambridge, I closed my talk by saying, “We should not rest until we make aging an absurdity.” We are now in a very different place. After a lot of patient explanation, publication of scientific results, conferences, and time, our community persuaded enough scientists of the feasibility of the damage repair approach to move SENS and SENS Research Foundation from the fringes of scientific respectability to the vanguard of a mainstream community of scientists developing medical therapies to tackle human aging. -
Age-Dependent Deterioration of Nuclear Pore Assembly in Mitotic
RESEARCH ARTICLE Age-dependent deterioration of nuclear pore assembly in mitotic cells decreases transport dynamics Irina L Rempel1, Matthew M Crane2, David J Thaller3, Ankur Mishra4, Daniel PM Jansen1, Georges Janssens1, Petra Popken1, Arman Aks¸it1, Matt Kaeberlein2, Erik van der Giessen4, Anton Steen1, Patrick R Onck4, C Patrick Lusk3, Liesbeth M Veenhoff1* 1European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen, Groningen, Netherlands; 2Department of Pathology, University of Washington, Seattle, United States; 3Department of Cell Biology, Yale School of Medicine, New Haven, United States; 4Zernike Institute for Advanced Materials, University of Groningen, Groningen, Netherlands Abstract Nuclear transport is facilitated by the Nuclear Pore Complex (NPC) and is essential for life in eukaryotes. The NPC is a long-lived and exceptionally large structure. We asked whether NPC quality control is compromised in aging mitotic cells. Our images of single yeast cells during aging, show that the abundance of several NPC components and NPC assembly factors decreases. Additionally, the single-cell life histories reveal that cells that better maintain those components are longer lived. The presence of herniations at the nuclear envelope of aged cells suggests that misassembled NPCs are accumulated in aged cells. Aged cells show decreased dynamics of transcription factor shuttling and increased nuclear compartmentalization. These functional changes are likely caused by the presence -
Longevity and Generosity. the Death of Death. July 2018. N° 112
Longevity and generosity. The death of death. July 2018. N° 112. Some people say, “Oh, you shouldn’t do enhancement” but the thing is we do enhancement all the time — to some extent, all aging reversal is enhancement. Vaccines are enhancement… I think I’m just now getting up to speed after 63 years of education. Aging reversal is something that will buy me and many of my colleagues a lot more time to make many more contributions, so you might consider that a meta-level contribution, if we can pull that off. World-renowned Harvard University biology researcher George Church (source). Theme of the month. How to contribute financially to research for a much longer healthy life Introduction If you have considerable financial means you can afford medical care more easily than less well-off citizens. But whether you are rich or not, with a good "genetic capital" or not, whatever your precautions and your anti-aging clinic visits, in the current state of knowledge your chances are low of living more than 100 years if you are a woman and beyond 95 years if you are of the weaker sex for longevity. And whatever happens, you will not live past 122 years for a woman et 116 years for a man. To go further will require complex and costly research. If informed citizens pay money to support this research, it will be positive in a direct way by funding the research. It will also be positive in that it will show the growing interest in these issues. What could you do about it? Moderate financial support If your financial means are limited or if you do not wish to make large donations, your action can still have an impact.